Citations

Clear

22 citation(s) found for "Burke, Carol A".

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
Lynch, Patrick M, Burke, Carol A. , Phillips, Robin, Morris, Jeffrey S. , Slack, Rebecca, Wang, Xuemei , Liu, Jun , Patterson, Sherri, Rodrı́guez-Bigas, Miguel A. , Half, Elizabeth , Bülow, Steffen, Latchford, Andrew , Clark, Sue, Ross, William A., Malone, Bonnie, Hasson, Hennie, Hawk, Ernest T. , Lynch, Patrick M, Sinicrope, Frank A. , Richmond, Ellen S. , Burke, Carol A

Mayo Clinic

Gut | March 20, 2015 | Volume: 65 | Issue: 2 | Pages: 286-295

10.1136/gutjnl-2014-307235 | PMID 25792707 Get It

Background and aim Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any. Methods The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria. Results 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was −13.0% for CXB+DFMO and −1.0% for CXB (p=0.69). Mean % change in adenoma burden was −40% (CXB+DFMO) vs −27% (CXB) (p=0.13). Video-based global polyp change was −0.80 for CXB+DFMO vs −0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02). Conclusions CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves. Trial registration number ClinicalTrials.gov number N01-CN95040.
A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network
Lowery, Jan T. , Horick, Nora , Kinney, Anita Y. , Garrett, Kathleen, Haile, Robert W. , Lindor, Noralane M. , Sandler, Robert S. , Burke, Carol A. , Hill, Deirdre A. , Ahnen, Dennis J. , Finkelstein, Dianne M. , Newcomb, Polly A. , Haile, Robert W , Sandler, Robert S , Burke, Carol A , Horick, Nora

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 5, 2014 | Volume: 23 | Issue: 4 | Pages: 601-610

10.1158/1055-9965.epi-13-1085 | PMID 24501379 Get It

Abstract Background: Individuals with a strong family history of colorectal cancer have significant risk for colorectal cancer, although adherence to colonoscopy screening in these groups remains low. This study assessed whether a tailored telephone counseling intervention can increase adherence to colonoscopy in members of high-risk families in a randomized, controlled trial. Methods: Eligible participants were recruited from two national cancer registries if they had a first-degree relative with colorectal cancer under age 60 or multiple affected family members, which included families that met the Amsterdam criteria for hereditary non-polyposis colon cancer (HNPCC), and if they were due for colonoscopy within 24 months. Participants were randomized to receive a tailored telephone intervention grounded in behavioral theory or a mailed packet with general information about screening. Colonoscopy status was assessed through follow-up surveys and endoscopy reports. Cox proportional hazards models were used to assess intervention effect. Results: Of the 632 participants (ages 25–80), 60% were female, the majority were White, non-Hispanic, educated, and had health insurance. Colonoscopy adherence increased 11 percentage points in the tailored telephone intervention group, compared with no significant change in the mailed group. The telephone intervention was associated with a 32% increase in screening adherence compared with the mailed intervention (HR, 1.32; P = 0.01). Conclusions: A tailored telephone intervention can effectively increase colonoscopy adherence in high-risk persons. This intervention has the potential for broad dissemination to healthcare organizations or other high-risk populations. Impact: Increasing adherence to colonoscopy among persons with increased colorectal cancer risk could effectively reduce incidence and mortality from this disease. Cancer Epidemiol Biomarkers Prev; 23(4); 601–10. ©2014 AACR.